P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
| Autori principali: | , , , , , , , , , , , , , , , , , |
|---|---|
| Natura: | Articolo |
| Lingua: | English |
| Pubblicazione: |
Wiley
2022-10-01
|
| Serie: | HemaSphere |
| Accesso online: | http://journals.lww.com/10.1097/01.HS9.0000890984.54786.aa |
| _version_ | 1827336180060913664 |
|---|---|
| author | Jozef Michalka Jana Marková Ľubica Gahérová Mária Maco Vít Procházka Jan Kořen Alice Sýkorová Pavla Štěpánková Kateřina Steinerová Lekaa Mohammad Juraj Ďuraš Barbora Velacková Tomáš Doležal Kateřina Benešová Marie Lukášová Andrea Janíková Zdeněk. Král. Heidi Móciková |
| author_facet | Jozef Michalka Jana Marková Ľubica Gahérová Mária Maco Vít Procházka Jan Kořen Alice Sýkorová Pavla Štěpánková Kateřina Steinerová Lekaa Mohammad Juraj Ďuraš Barbora Velacková Tomáš Doležal Kateřina Benešová Marie Lukášová Andrea Janíková Zdeněk. Král. Heidi Móciková |
| author_sort | Jozef Michalka |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:27:34Z |
| format | Article |
| id | doaj.art-09f29971b9f04237b6e4c5af2125fe65 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:27:34Z |
| publishDate | 2022-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-09f29971b9f04237b6e4c5af2125fe652024-03-02T06:57:06ZengWileyHemaSphere2572-92412022-10-016484910.1097/01.HS9.0000890984.54786.aa202210005-00104P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.Jozef Michalka0Jana Marková1Ľubica Gahérová2Mária Maco3Vít Procházka4Jan Kořen5Alice Sýkorová6Pavla Štěpánková7Kateřina Steinerová8Lekaa Mohammad9Juraj Ďuraš10Barbora Velacková11Tomáš Doležal12Kateřina Benešová13Marie Lukášová14Andrea Janíková15Zdeněk. Král.16Heidi Móciková171 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic2 Department of Hematology, University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic2 Department of Hematology, University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic2 Department of Hematology, University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic3 Department of Hematology, University Hospital Olomouc and Palacky University Olomouc, Czech Republic4 st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic5 th Department of Internal medicine - Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic5 th Department of Internal medicine - Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic6 Department of Hematooncology, Charles University Hospital, Pilsen, Czech Republic6 Department of Hematooncology, Charles University Hospital, Pilsen, Czech Republic7 Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic8 Value Outcomes, Prague, Czech Republic8 Value Outcomes, Prague, Czech Republic4 st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic3 Department of Hematology, University Hospital Olomouc and Palacky University Olomouc, Czech Republic1 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic1 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic2 Department of Hematology, University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, Prague, Czech Republichttp://journals.lww.com/10.1097/01.HS9.0000890984.54786.aa |
| spellingShingle | Jozef Michalka Jana Marková Ľubica Gahérová Mária Maco Vít Procházka Jan Kořen Alice Sýkorová Pavla Štěpánková Kateřina Steinerová Lekaa Mohammad Juraj Ďuraš Barbora Velacková Tomáš Doležal Kateřina Benešová Marie Lukášová Andrea Janíková Zdeněk. Král. Heidi Móciková P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic. HemaSphere |
| title | P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic. |
| title_full | P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic. |
| title_fullStr | P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic. |
| title_full_unstemmed | P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic. |
| title_short | P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic. |
| title_sort | p104 consolidation therapy with brentuximab vedotin after autologous stem cell transplantation for relapsed refractory hodgkin lymphoma in the czech republic |
| url | http://journals.lww.com/10.1097/01.HS9.0000890984.54786.aa |
| work_keys_str_mv | AT jozefmichalka p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT janamarkova p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT lubicagaherova p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT mariamaco p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT vitprochazka p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT jankoren p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT alicesykorova p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT pavlastepankova p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT katerinasteinerova p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT lekaamohammad p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT jurajduras p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT barboravelackova p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT tomasdolezal p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT katerinabenesova p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT marielukasova p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT andreajanikova p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT zdenekkral p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic AT heidimocikova p104consolidationtherapywithbrentuximabvedotinafterautologousstemcelltransplantationforrelapsedrefractoryhodgkinlymphomaintheczechrepublic |